Literature DB >> 25787864

High efficiency intranasal drug delivery using Intravail® alkylsaccharide absorption enhancers.

Edward T Maggio1, Dennis J Pillion.   

Abstract

A new class of alkylsaccharide transmucosal delivery enhancement agents are described that overcome the principal limitations preventing broad acceptance of intranasal administration for many potential applications in systemic drug delivery, namely, poor transmucosal absorption and damage to the nasal mucosa. This review will describe recent developments in use of these excipients in human clinical trials and preclinical studies along with their chemical and pharmacological properties and explore commercial implications of the use of these excipients in introduction of new intranasal formulations of peptidic and nonpeptidic drugs.

Entities:  

Year:  2013        PMID： 25787864     DOI： 10.1007/s13346-012-0069-z

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN： 2190-393X            Impact factor:   4.617


  34 in total

Review 1.  Transport of drugs from the nasal cavity to the central nervous system.

Authors:  L Illum
Journal:  Eur J Pharm Sci       Date:  2000-07       Impact factor: 4.384

2.  n-Dodecyl-β-D-maltoside inhibits aggregation of human interferon-β-1b and reduces its immunogenicity.

Authors:  Robert A Rifkin; Edward T Maggio; Sonny Dike; Douglas A Kerr; Michael Levy
Journal:  J Neuroimmune Pharmacol       Date:  2010-06-08       Impact factor: 4.147

Review 3.  Mucosal drug delivery: membranes, methodologies, and applications.

Authors:  Yifan Song; Yiping Wang; Rashmi Thakur; Victor M Meidan; Bozena Michniak
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2004       Impact factor: 4.889

4.  Autoxidation of polyoxyethylenic non-ionic surfactants and of polyethylene glycols.

Authors:  R Hamburger; E Azaz; M Donbrow
Journal:  Pharm Acta Helv       Date:  1975

Review 5.  Intranasal drug delivery: how, why and what for?

Authors:  Anaísa Pires; Ana Fortuna; Gilberto Alves; Amílcar Falcão
Journal:  J Pharm Pharm Sci       Date:  2009       Impact factor: 2.327

6.  Intranasal administration of diazepam aiming at the treatment of acute seizures: clinical trials in healthy volunteers.

Authors:  S Gizurarson; F K Gudbrandsson; H Jónsson; E Bechgaard
Journal:  Biol Pharm Bull       Date:  1999-04       Impact factor: 2.233

7.  AFPep: an anti-breast cancer peptide that is orally active.

Authors:  James A Bennett; Lori DeFreest; Ikenna Anaka; Hamid Saadati; Sujata Balulad; Herbert I Jacobson; Thomas T Andersen
Journal:  Breast Cancer Res Treat       Date:  2006-03-15       Impact factor: 4.872

8.  Synthetic peptide derived from alpha-fetoprotein inhibits growth of human breast cancer: investigation of the pharmacophore and synthesis optimization.

Authors:  L A DeFreest; F B Mesfin; L Joseph; D J McLeod; A Stallmer; S Reddy; S S Balulad; H I Jacobson; T T Andersen; J A Bennett
Journal:  J Pept Res       Date:  2004-05

9.  Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers.

Authors:  V D Ivaturi; J R Riss; R L Kriel; J C Cloyd
Journal:  Acta Neurol Scand       Date:  2009-05-14       Impact factor: 3.209

10.  The effect of benzalkonium chloride on rabbit nasal mucosa in vivo: an electron microscopy study.

Authors:  Sebahattin Cüreoğlu; Murat Akkuş; Ustün Osma; Mehmet Yaldiz; Faruk Oktay; Belgin Can; Cengiz Güven; Muhammet Tekin; Faruk Meriç
Journal:  Eur Arch Otorhinolaryngol       Date:  2002-06-18       Impact factor: 2.503
View more
  9 in total

Review 1.  Materials and methods for delivery of biological drugs.

Authors:  Alexander N Zelikin; Carsten Ehrhardt; Anne Marie Healy
Journal:  Nat Chem       Date:  2016-10-21       Impact factor: 24.427

2.  Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.

Authors:  Philip Krieter; Shwe Gyaw; Roger Crystal; Phil Skolnick
Journal:  J Pharmacol Exp Ther       Date:  2019-04-02       Impact factor: 4.030

3.  Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects.

Authors:  Philip Krieter; C Nora Chiang; Shwe Gyaw; Phil Skolnick; Rebekah Snyder
Journal:  Drug Metab Dispos       Date:  2019-04-16       Impact factor: 3.922

4.  Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy.

Authors:  James W Wheless; Ian Miller; R Edward Hogan; Dennis Dlugos; Victor Biton; Gregory D Cascino; Michael R Sperling; Kore Liow; Blanca Vazquez; Eric B Segal; Daniel Tarquinio; Weldon Mauney; Jay Desai; Adrian L Rabinowicz; Enrique Carrazana
Journal:  Epilepsia       Date:  2021-08-21       Impact factor: 6.740

5.  Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats.

Authors:  Davin Rautiola; Patricia D Maglalang; Narsihmulu Cheryala; Kathryn M Nelson; Gunda I Georg; Jared M Fine; Aleta L Svitak; Katherine A Faltesek; Leah R Hanson; Usha Mishra; Lisa D Coles; James C Cloyd; Ronald A Siegel
Journal:  J Pharmacol Exp Ther       Date:  2019-03-05       Impact factor: 4.030

6.  Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose.

Authors:  Philip Krieter; Shwe Gyaw; C Nora Chiang; Roger Crystal; Phil Skolnick
Journal:  J Clin Pharmacol       Date:  2019-01-30       Impact factor: 3.126

Review 7.  Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes.

Authors:  Maliheh Ghadiri; Paul M Young; Daniela Traini
Journal:  Pharmaceutics       Date:  2019-03-11       Impact factor: 6.321

Review 8.  Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics.

Authors:  Carlos Bendicho-Lavilla; Iria Seoane-Viaño; Francisco J Otero-Espinar; Asteria Luzardo-Álvarez
Journal:  Acta Pharm Sin B       Date:  2021-08-10       Impact factor: 11.413

9.  Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: A phase 1, open-label study.

Authors:  Robert Edward Hogan; Daniel Tarquinio; Michael R Sperling; Pavel Klein; Ian Miller; Eric B Segal; Adrian L Rabinowicz; Enrique Carrazana
Journal:  Epilepsia       Date:  2020-04-27       Impact factor: 5.864
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.